Pilot Study of Topical Trifluridine for the Treatment of Acy… : JAIDS Journal of Acquired Immune Deficiency Syndromes

Pilot Study of Topical Trifluridine for the Treatment of Acy... : JAIDS Journal of Acquired Immune Deficiency Syndromes

VIROPTIC sterile ophthalmic solution contains 1% trifluridine in an aqueous solution with acetic acid and sodium acetate (buffers), sodium chloride, and thimerosal 0.001% (added as a preservative). Accepting the fact that you have herpes make it easier to let others into your life. Once your condition improves, you may need to keep using the medication 4 times daily (up to 5 drops per day) for another 7 days. Sorry for the lack of brevity, but – I don’t think I can keep this short. Although documented in vitro viral resistance to trifluridine has not been reported following multiple exposures to VIROPTIC (trifluridine) , the possibility of the development of viral resistance exists. Quercetin reduces intraoellular replication of the herpes virus and viral infectivity. Some strains of adenovirus are also inhibited in vitro.

Immediately use your finger to apply pressure to the inside corner of the eye for 1 to 2 minutes. Herpes simplex esophagitis is well recognized in immunosuppressed subjects, but it is infrequent in immunocompetent patients. Genital herpes is caused by the herpes simplex virus – usually the strain known as HSV-2. Viroptic (trifluridine, GlaxoSmithKline) is the cornerstone of topical treatment for herpes simplex keratitis. If you are pregnant and have genital herpes, you may be offered herpes medicine towards the end of your pregnancy to reduce the risk of having any symptoms and passing the disease to your baby. New antiviral medications have expanded treatment options for the two most common cutaneous manifestations, orolabial and genital herpes. Both Acyclovir and Valacyclovir work to decrease the severity, intensity, and duration of outbreaks and are available in a variety of dosing strategies (depending on the preference of the patient).

The treatment of individuals infected with the herpes simplex virus depends on several factors. Many people choose to treat herpes simplex because treatment can relieve symptoms and shorten an outbreak. In other clinical studies, VIROPTIC was evaluated in the treatment of herpes simplex virus keratitis in patients who were unresponsive or intolerant to the topical administration of idoxuridine or vidarabine. The chance of the lesions fully aborting is almost twice as likely when treatment is begun less than six hours after the onset of symptoms. The mean time to corneal re-epithelialization was 6 days for patients with dendritic ulcers and 12 days for patients with geographic ulcers. For the treatment of first episode genital herpes, the dose of oral acyclovir is 200 mg orally five times per day, or 400 mg orally three times per day (Table64. If you get diagnosed with herpes, talk to your doctor about medical-strength treatment options.

The following drugs and medications are in some way related to, or used in the treatment of Herpes Simplex. The treatment of individuals infected with the herpes simplex virus depends on several factors. Foscarnet is the only licensed drug effective for the treatment of ACV-R HSV infection (10,11,14,15,22,28). The following drugs and medications are in some way related to, or used in the treatment of Herpes Simplex. Anecdotal reports suggest that the use of topical ophthalmic trifluridine could be effective for the treatment of ACV-R HSV infections in patients with AIDS (29,30). While HSV-2 infections are spread by coming into contact with a herpes sore, the AAD reports that most people get HSV-1 from an infected person who is asymptomatic, or does not have sores. Studies in humans have not shown that caffeine (contained in some of these combination medicines) causes birth defects.

Learn about Herpes Simplex Keratitis symptoms, diagnosis and treatment in the Merck Manual. Pregnancy:  Teratogenic Effects:   Pregnancy Category C. The in vitro IC50 of trifluridine against HSV-1 has been reported to range from 0.2 to 1.7 μg/ml, with HSV-2 susceptibility being more variable (31). Certain antibiotics haw get a lofty Vd, and thence counsel to a soft Cmax during sepsis. In both rats and rabbits, 1 mg/kg/day (5 times the estimated human exposure) was a no-effect level. Although the estimated median time to complete healing was longer in our study compared to that reported for intravenous foscarnet (15), the estimated median time to 50% reduction in lesion area was only 2.4 weeks. Of the 17 patients who did not have complete healing, the overall median reduction in lesion area was 75%, and the median duration of therapy was 5.3 weeks.

Follow-up visits at the NIH eye clinic are scheduled as required by the patient’s condition. This may be a reflection of the relatively slow healing rate and intercurrent clinical problems characteristic of patients with advanced HIV disease. Multum’s drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The drug should not be prescribed for nursing mothers unless the potential benefits outweigh the potential risks. (32) noted a correlation with pain resolution and healing of HSV lesions in other immunocompromised hosts. Less commonly, the epithelial basement membrane may house the latent virus. In a recent review of 160 patients with AIDS and ACV-R HSV disease (33), spontaneous resolution of lesions was not reported.

– Is there such a thing as a “herpes specialist” – and how would you go about finding one? Hours later, a staff member confirmed via telephone that the patient was doing well. This is particularly true for viral infection of the nerve cells of the dorsal root ganglia that are out of range of the immune system. Therefore, we think it is unlikely that the response to topical trifluridine in our study was fortuitous. Genital herpes is a sexually transmitted disease (STD) caused by the herpes simplex virus Type I (HSV-1) and Type II (HSV-2). If there are no signs of improvement after 7 days of therapy or complete re-epithelialization has not occurred after 14 days of therapy, other forms of therapy should be considered. Facial lesions tended to be smaller and were more accessible and amenable to treatment, although it has been reported that facial HSV lesions in patients with HIV infection respond more favorably to antiviral therapy than those in the perirectal area (22).

In addition, smaller lesions that responded more rapidly in terms of reduction in area and pain may have resulted in increased medication compliance. Little clinical toxicity is described, but pregnant women should use it with caution. PCN allergy. Reformulation of trifluridine in a more convenient vehicle, such as azone and propylene glycol as described by Spruance et al. (34), might well result in enhanced clinical responses. Our data suggest that a more timely diagnosis of ACV-R HSV disease when lesions are smaller is important in the response to topical trifluridine. In patients with AIDS, mucocutaneous HSV lesions not responding to acyclovir therapy within 14 days should be assumed to be caused by resistant viruses.
Pilot Study of Topical Trifluridine for the Treatment of Acy... : JAIDS Journal of Acquired Immune Deficiency Syndromes

In those cases, alternative therapy should be started as soon as viral cultures for in vitro determination of acyclovir resistance have been obtained. Treatment with a topical agent such as trifluridine, if systemic therapy with foscarnet is not otherwise indicated, should be considered. In conclusion, topical trifluridine may be of benefit in certain selected patients with AIDS and ACV-R chronic mucocutaneous HSV disease. Topical therapy with trifluridine was well tolerated with no dose-limiting toxicity. If you do not provide the last 5 digits of your SSN on the next page you will not be able to access a CME credit transcript. Formulation of trifluridine in a more convenient delivery vehicle warrants further investigation. Acknowledgment: We would like to thank Kathi Kapell, M.S.

for her tireless efforts in the determination of the in vitro antiviral susceptibility data. We are also indebted to Joan Drucker, M.D., Burroughs Wellcome, for providing Viroptic (trifluridine) ophthalmic solution 1% and Polysporin (polymyxin B/bacitracin). This article was presented in part at the Eighth International Conference on AIDS, Amsterdam, Netherlands, July 19-24, 1992 (abstract WeB 1056). Informed consent for participation in this study was obtained from all patients in accordance with the guidelines on human experimentation of the U.S. This is why we keep a supply of the AdenoPlus (Nicox) adenoviral testing kits at the ready in our examination rooms, which can aid an uncertain red eye diagnosis. Research reported herein was supported in part by the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases and the General Clinical Research Center Units funded by the National Center for Research Resources. The following clinicians of the AIDS Clinical Trials Group participated in this study: Fred Valentine and Lauren DeHolczer, New York University, New York; Denise Weaver, John Pottage, and Pam Urbanski, Rush Medical College, Chicago; John G.

Bartlett, Rebecca Becker, and Vivian Rexroad, Johns Hopkins University, Baltimore; Robert Schooley and Graham Ray, University of Colorado Health Science Center, Denver; William Powderly, Mary Gould, and Michael Royal, Washington University School of Medicine, St. Louis; Julie Calo and Rebecca Coleman, University of California, San Francisco; Peter Mariuz, Edward Weissman, and Ruth Ann Burk, State University of New York, Stony Brook; Joan Avato and Linda Mangini, University of Massachusetts, Worcester; and Michael Grieco, Department of Medicine, St. Luke’s-Roosevelt Hospital Center, Columbia University, New York. Use this medication regularly in order to get the most benefit from it. 1995, pp. Mucocutaneous herpes simplex virus infections in immunocompromised patients: a model for evaluation of topical antiviral agents. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS.

The etiology of HSE was proven serologically, by repeated detection of herpes simplex virus (HSV) -specific DNA sequences in cerebrospinal fluid (CSF) with polymerase chain reaction (PCR) and was supported by cerebral imaging. Erlich KS, Jacobson MA, Koehler JE, et al. Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS): an uncontrolled trial. Ann Intern Med 1989;110:710-3. 11. Chatis PA, Miller CH, Schrager LE, Crumpacker CS. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome.

N Engl J Med 1989;320:297-300. 14. Birch CJ, Tachedjian G, Doherty RR, Hayes K, Gust ID. Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. J Infect Dis 1990;162:731-4. 15. Safrin S, Crumpacker CS, Chatis P, et al.

A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991;325:551-5. 21. Hill EL, Hunter GA, Ellis MN. In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1991;35:2322-8. 22.

Safrin S, Elbeik T, Phan L, et al. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1994;38:1246-50. 29. Weaver D, Weissbach N, Kapell K, Benson CA, Pottage JC, Kessler HA. Topical trifluridine (Trifluridine) treatment of acyclovir-resistant (ACV-R) herpes simplex disease [Abstract 507]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago).

Washington, DC: American Society for Microbiology, 1991. 30. Birch CJ, Tyssen DP, Tachedjian G, et al. Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections. 7. 31. Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS.

Minimal assistance was required to help her into a wheelchair and she was taken to her automobile, which was driven by her daughter. This treatment failure highlights the necessity of maintaining a healthy underlying immune system in resisting HSV and the important involvement of dietary Zn2+ in maintaining that immunity. 34. Spruance SL, McKeough M, Sugibayashi K, Robertson F, Gaede P, Clark DS. Effect of azone and propylene glycol on penetration of trifluorothymidine through skin and efficacy of different topical formulations against cutaneous herpes simplex virus infections in guinea pigs. Antimicrob Agents Chemother 1984;26:819-23.

You may also like